Nitric oxide generating system

Abstract

To eliminate the need for nitric oxide tanks (i.e., NO in compressed gas cylinders) in a nitric oxide (NO) generating system.SOLUTION: A nitric oxide (NO) generating system is provided which includes an NO generating formulation and an inhalation device in operative contact with the NO generating formulation. The NO generating formulation comprises a stable NO donor / adduct, a hydrophilic binder, and an additive. The additive is to control a rate of release of NO from the NO donor / adduct after the formulation is exposed to an effective amount of water, water vapor, or blue or ultraviolet (UV) light. This eliminates the need for nitric oxide tanks (i.e., NO in compressed gas cylinders) in the nitric oxide (NO) generating system, thereby simplifying the systems / devices and thus reducing the cost of the systems / devices.SELECTED DRAWING: Figure 26

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Application No. 62 / 891,129, filed August 23, 2019, the contents of which are incorporated herein by reference in their entirety. [Background technology]

[0002] In the human body, nitric oxide (NO) can be produced by any of several isoforms of the enzyme nitric oxide synthase (NOS). NO is central to mammalian immune responses and defenses and is a cytotoxic agent in the mechanism used by macrophages to kill L. major, M. bovis, and M. tuberculosis, among numerous bacterial species. NO is also an effective antiviral agent, exhibiting activity against rhinoviruses that cause the common cold. NO is produced by immune cells (e.g., macrophages, neutrophils, lymphocytes) and airway epithelial cells (e.g., conductive respiratory epithelial cells) primarily from L-arginine in the airways (e.g., upper respiratory tract) via inducible nitric oxide synthase (iNOS). Deficient NO production can diminish immune responses and / or microbial biofilm formation. Deficient nasal NO levels have been associated with disorders such as primary ciliary dyskinesia and chronic rhinosinusitis (CRS), and potentially with impaired ability to combat cold-causing viral agents. Some physiological properties of NO include its use as an anti-inflammatory, anticoagulant, and / or antibacterial agent.

[0003] The use of NO in inhaled therapy is also being studied. Inhaled nitric oxide has been used to treat pulmonary failure and has been shown to promote pulmonary arterial vasodilation and decrease pulmonary vascular resistance. Inhaled nitric oxide has also been approved by the U.S. Food and Drug Administration (FDA) to treat newborns with hypoxemic respiratory failure. It has also been shown to improve oxygenation and reduce the need for extracorporeal membrane oxygenation. Summary of the Invention

[0004] An example of a nitric oxide (NO) generating system includes an NO-generating formulation, the NO-generating formulation comprising a stable NO donor / adduct, a hydrophilic binder, and an additive that controls the rate of release of NO from the NO donor / adduct after the formulation is exposed to an effective amount of water, water vapor, or blue light or ultraviolet (UV) light, and an inhalation device in operative contact with the NO-generating formulation.

[0005] Another example of a nitric oxide (NO) generating system includes an NO-generating formulation, the NO-generating formulation comprising a stable NO donor / adduct, a hydrophilic binder, and an alkaline material selected from the group consisting of sodium carbonate, a mixture of sodium carbonate and sodium bicarbonate, sodium hydroxide, potassium hydroxide, disodium hydrogen phosphate, trisodium phosphate, and combinations thereof, wherein the alkaline material causes the pH of the NO-generating formulation to be 8.5 or higher, thereby destabilizing the NO donor / adduct to release NO after the formulation is exposed to an effective amount of water vapor or a hydration liquid; and an inhalation device in operative contact with the NO-generating formulation.

[0006] Yet another example of a nitric oxide (NO) generating system includes an NO-permeable container including an attachment mechanism and an NO-generating formulation contained within the NO-permeable pouch, the NO-generating formulation including a stable NO donor / adduct that is activatable upon exposure to an effective amount of water vapor, a hydrating fluid, or blue or ultraviolet (UV) light.

[0007] Yet another example of an NO generating system includes a face mask; a housing secured to the face mask, the housing including a reservoir having an NO-permeable wall positioned between the housing and an interior of the face mask; and an NO generating formulation contained within or adapted to be introduced into the reservoir, the NO generating formulation including a nitrite salt adapted to generate NO when the NO generating formulation is exposed to an effective amount of an acidic buffer solution.

[0008] Features of embodiments of the present disclosure will become apparent by reference to the following detailed description and drawings. In the drawings, like reference numerals correspond to similar, but perhaps not identical, components. For brevity, reference numerals or features having previously described functions may or may not be described in relation to other drawings in which they appear. In some of the figures (e.g., Figures 9-20), data are presented for nitric oxide (NO) release profiles or kinetics (e.g., PPB or PPBV, Y-axis) as a function of time (X-axis) corresponding to compressed pellets of various formulations. In these figures, the data represent a wide range of values ​​due to variations associated with uneven hydration of the pellets. [Brief explanation of the drawings]

[0009] [Figure 1A] FIG. 1A is a photograph showing an example NO-generating formulation formed as two single pellets, each within a plastic sheath. [Figure 1B] FIG. 1B is a photograph showing an example of an NO-generating formulation formed as a single pellet without a plastic sheath. [Figure 2-1] 2A and 2B are schematic diagrams of an exemplary face mask inhalation device with the NO-generating formulation holding housing in an open position (FIG. 2A) and a closed position (FIG. 2B). [Figure 2-2] FIG. 2C is a side view of the face mask inhalation device of FIG. 2B, with the NO-generating formulation positioned in close proximity to the area where the user's nose and mouth will be located. [Figure 3-1] 3A and 3B are schematic diagrams of another exemplary face mask inhalation device, showing the NO-generating formulation holding housing in an open position (FIG. 3A) and a closed position (FIG. 3B). [Figure 3-2] FIG. 3C is a side view of the face mask inhalation device of FIG. 3B, showing the NO-generating formulation in proximity to the area where the user's nose and mouth will be located. [Figure 4]Figure 4A is a schematic side view of another example face mask inhalation device, and Figure 4B is a cross-sectional view of multiple NO-generating formulation pellets within a housing, taken along line 4B-4B of Figure 4A. [Figure 5] FIG. 5 is a schematic side and end view of the example face mask inhalation device of FIG. [Figure 6] FIG. 6 is a schematic side view of yet another example face mask inhalation device. [Figure 7] FIG. 7 is a schematic side view of yet another example face mask inhalation device. [Figure 8] FIG. 8 is a reverse schematic diagram illustrating an example inhalation system inhalation device that includes a nasal cannula. [Figure 9] FIG. 9 is a graph showing nitric oxide (NO) release profiles from exemplary NO-generating formulations over time. [Figure 10] FIG. 10 is a graph showing the nitric oxide (NO) release kinetics of GSNO from another exemplary NO-generating formulation. [Figure 11] FIG. 11 is a graph showing the nitric oxide (NO) release profile over time from yet another exemplary NO-generating formulation. [Figure 12] FIG. 12 is a graph showing the nitric oxide (NO) release profile over time from yet another exemplary NO-generating formulation. [Figure 13] FIG. 13 is a graph showing the nitric oxide (NO) release profile from the example NO-generating formulation of FIG. 12 over time. [Figure 14] FIG. 14 is a graph showing the nitric oxide (NO) release profile over time from yet another exemplary NO-generating formulation. [Figure 15A] FIG. 15A is a graph showing nitric oxide (NO) release profiles from additional exemplary NO-generating formulations over time. [Figure 15B] FIG. 15B is a graph showing nitric oxide (NO) release kinetics of the example GSNO formulation of FIG. 15A under various relative humidity conditions. [Figure 16]FIG. 16 is a graph showing the nitric oxide (NO) release profile over time from yet another exemplary NO-generating formulation. [Figure 17] FIG. 17 is a graph showing the nitric oxide (NO) release profile over time from yet another exemplary NO-generating formulation. [Figure 18] FIG. 18 is a graph showing the nitric oxide (NO) release profile over time from yet another exemplary NO-generating formulation. [Figure 19] FIG. 19 is a graph showing the nitric oxide (NO) release profile over time from yet another exemplary NO-generating formulation. [Figure 20] FIG. 20 is a graph showing the nitric oxide (NO) release profile over time from yet another exemplary NO-generating formulation. [Figure 21] FIG. 21 is a schematic diagram showing an example of an NO generating system that includes a container, an adhesive that can be formed into a disk, tablet, or other shape, and a release liner. [Figure 22] FIG. 22 is a schematic diagram showing the NO generation system of FIG. 21 attached to an inhalation device. [Figure 23] FIG. 23 is a schematic diagram showing another example of an NO generation system attached to an inhalation device. [Figure 24] Figure 24A is a schematic diagram showing an example of a photoactivated NO generation system attached to an inhalation device, and Figure 24B is a schematic diagram showing another example of a photoactivated NO generation system attached to an inhalation device. [Figure 25-1] FIG. 25A is a perspective schematic diagram showing a nasal vent plug containing an NO-generating formulation in solid form. [Figure 25-2] Figure 25B is a perspective schematic diagram showing a nasal vent plug including a reservoir for receiving an NO-generating formulation in liquid form, and Figure 25C is a perspective schematic diagram showing a nasal vent plug including a light-activated NO-generating system. [Figure 26] FIG. 26 is a schematic diagram showing yet another example of an NO generation system attached to an inhalation device. [Figure 27]FIG. 27 is a graph showing NO levels (ppm, left Y-axis) and NO2 levels (ppm, right Y-axis) versus time (hours, X-axis). DETAILED DESCRIPTION OF THE INVENTION

[0010] Nitric oxide (NO) is a potent antithrombotic, anti-inflammatory, antibacterial, and antiviral agent. In vivo NO deficiency can be genetic, associated with polymorphisms, or caused by pathologies or pathogens that exploit upstream regulation of NO production. Defective NO production impairs mucociliary function (which is one of the primary innate immune defense mechanisms in the airway epithelium and is directly correlated with ciliary beat frequency), predisposing to microbial infections and / or promoting the persistence of bacterial biofilms that are resistant to antibiotics.

[0011] Inhaled NO therapy introduces NO into a patient's lungs, thereby enhancing mucociliary function, reducing susceptibility to microbial infection, and / or promoting bacterial biofilm resistance. NO has been shown to be effective against the SARS coronavirus and may also be effective in treating other viruses, such as COVID-19 or SARS-CoV-2. The use of inhaled nitric oxide may also prove beneficial in other areas, such as during lung transplants, for the treatment of pulmonary hypertension, as an inhaled disinfectant, and for the treatment of other systemic conditions, including ischemic stroke, heart attack, thrombosis, and traumatic brain injury.

[0012] Disclosed herein are exemplary moisture (e.g., water vapor)-activated, hydration fluid-activated, acidic buffer-activated, or light-activated nitric oxide gas generating systems / devices in which nitric oxide (NO) gas is generated on demand from an inhalation device in contact with exemplary moisture-activated, hydration fluid-activated, acidic buffer-activated, or light-activated NO-generating formulations (also referred to herein as NO-releasing formulations).

[0013] An example of an NO-generating formulation includes a stable NO donor / adduct (e.g., S-nitrosothiol (RSNO) powder or nitroprusside). In addition to the stable NO donor / adduct, some examples of the NO-generating formulation further include a hydrophilic binder and an additive. The additive is adapted to control (promote) the release rate of NO from the stable NO donor / adduct after the formulation is exposed to an effective amount of water vapor, a hydrating liquid, or blue or ultraviolet (UV) light.

[0014] In some examples, the NO-generating formulation is in the form of a solid (e.g., pellet / tablet / disc) containing a stable NO donor / adduct (e.g., RSNO (GSNO)), an additive (e.g., a reaction promoter), and a hydrophilic binder. In some examples, a lubricant and / or an inert material and / or a pH-controlling material may be included. In some other examples, when the NO-generating formulation is alkaline (e.g., pH greater than 8.5), the additive / reaction promoter is not included.

[0015] In other examples, the NO-generating formulation is in the form of a solution or dispersion. In some of these examples, a solid form containing a stable NO donor / adduct (e.g., RSNO (GSNO)), and in some cases, an additive and a hydrophilic binder, is mixed with a hydration liquid. In other examples, a liquid form of the NO-generating formulation contains a nitrite salt and an acidic buffer. The formulation may also contain an additive and / or an oxygen scrubber as described herein.

[0016] The terms "nitric oxide adduct" (NO adduct) and "NO donor" refer to compounds and functional groups capable of donating and / or releasing NO under typical conditions (e.g., humidity, hydration) or upon exposure to light of a specific wavelength. As such, the term "moisture-activated NO-releasing formulation" as used herein includes NO donors / adducts capable of releasing NO gas molecules upon exposure to an effective amount of water vapor and / or hydrating liquid (e.g., water). In one example, a suitable amount of water vapor can be found under conditions ranging from about 40% relative humidity to as high as 100% relative humidity (see, e.g., Figure 15B). Similarly, a "light-activated NO-releasing formulation" includes NO donors / adducts capable of releasing NO gas molecules upon exposure to light of a specific wavelength at various intensities to produce a desired amount of NO. Some examples of NO donors / adducts disclosed herein can be activated by two or more of moisture, hydrating liquid, and light. Suitable NO adducts are also, broadly speaking, adducts that exhibit the ability to exhibit process stability.

[0017] Additionally, the term "acid buffer-activated NO-releasing formulation" includes nitrites that generate NO gas molecules when exposed to an acid buffer that brings the formulation to a pH of greater than 4 to about 7.5. In some instances, the pH is from about 4.5 to about 7.0, or from about 4.1 to about 6.9.

[0018] In some of the examples disclosed herein, the nitric oxide-generating formulation is specifically formulated in a solid form (e.g., a single solid or a single densely packed solid mass using pressure (e.g., about 25-50 kn)), such as a pellet, tablet, or disk. The solid form produces gaseous NO over a wide range (about 50 ppbv to over about 50,000 ppbv) upon exposure to humidified air (e.g., from the user's inhaled / exhaled breath, from an air humidifier, etc.). This range covers the range demonstrated to be therapeutically effective for inhalation therapy. As used herein, "densely packed" refers to a density similar to that of a crystalline material, rather than a granular one. The NO-generating formulation enables spontaneous delivery of NO over an extended period of time while the user is in contact with the example inhalation device containing the moisture-activated NO-generating formulation.

[0019] In other examples disclosed herein, the nitric oxide-generating formulation is in solid form and contained within a container. The container is attached to or introduced into an inhalation device. In some cases, the container is permeable to humidified air and NO. This type of container allows humidified air to contact the nitric oxide-generating formulation and also allows the generated gaseous NO to be released from the container. In other cases, the container is transparent to visible blue and / or cyan light (wavelengths of about 400 nm to about 490 nm and / or about 490 nm to about 520 nm) and / or ultraviolet light (wavelengths of about 10 nm to about 400 nm) and is NO-permeable. This type of container allows light to contact the nitric oxide-generating formulation and also allows the generated gaseous NO to be released from the container.

[0020] In other examples disclosed herein, the nitric oxide-generating formulation is in solid or powder form sealed within a package that prevents moisture from outside humidity and liquids from reaching the nitric oxide-generating formulation until the formulation is returned and poured into a reservoir, such as the reservoir shown in FIG.

[0021] In other examples disclosed herein, the nitric oxide-generating formulation is a coating or powder that is applied to an absorbent pad (e.g., a PIG® absorbent pad) and placed into a device such as that depicted in Figure 25B, which produces NO when moisture or liquid is added to the device.

[0022] The systems / devices disclosed herein are relatively compact and eliminate the need for nitric oxide tanks (i.e., NO in compressed gas cylinders), which simplifies the system / device and reduces the cost of the system / device.

[0023] The use of the exemplary NO-releasing formulations disclosed herein to form inhalable nitric oxide has been shown to be effective in fighting disease, including prophylactic use, reducing infectious agents (e.g., viruses, bacteria, and fungi), treating pulmonary failure, improving pulmonary arterial vasodilation, and reducing pulmonary vascular resistance and other conditions including inflammation, coagulation, and infection. As discussed above, inhalable nitric oxide can also be used to treat newborns with hypoxemic respiratory failure and can improve oxygenation and reduce the need for extracorporeal membrane oxygenation. The use of the exemplary NO-releasing formulations disclosed herein to generate inhalable nitric oxide has also been shown to be beneficial in other areas, such as during lung transplantation, for the treatment of pulmonary hypertension, as an inhaled disinfectant, and for air disinfection.

[0024] For example, the use of the exemplary NO-releasing formulations disclosed herein generally increases NO levels both externally and internally in epithelial cells and immune cells, which can also help regulate ciliary beating frequency. As such, the nitric oxide-generating formulations described herein can help restore / improve mucociliary function (which, as noted above, is directly correlated with ciliary beating frequency). Restored / improved mucociliary function can enhance defenses against chronically colonizing pathogens and reduce or prevent disease perpetuation. Additionally, nitric oxide released from NO-releasing formulations has direct bactericidal, antiviral, and antibacterial activity against most types of bacteria, viruses, and fungi that can infect the sinuses and other parts of the respiratory system. Therefore, the exemplary nitric oxide-generating formulations may be beneficial for treating or preventing respiratory tract infections, including upper respiratory tract infections such as CRS.

[0025] NO generating agent

[0026] Some example NO-generating formulations include a stable NO donor / adduct. In some cases, these example NO-generating formulations include a stable NO donor / adduct, a hydrophilic binder, and an additive.

[0027] Examples of moisture-activated stable NO donors / adducts include, for example, S-nitrosothiol (RSNO) powder, or nitroprusside.

[0028] The moisture-activated RSNOs selected for the nitric oxide-generating formulations are species that occur naturally in the human body or another living organism, or species that can be degraded to species that occur naturally in the human body, or drugs suitable for human use (i.e., ingestion, consumption, etc.). In any of the examples disclosed herein, the moisture-activated RSNOs or RSNO powders are selected from S-nitrosoglutathione (GSNO, occurring naturally in the human body), S-nitroso-cysteine ​​(CYSNO, occurring naturally in the human body), S-nitroso-N-acetyl-penicillamine (SNAP, degraded to the drug penicillamine), S-nitroso-penicillamine, and S-nitroso-albumin (naturally occurring in vertebrates).

[0029] S-nitrosoglutathione (GSNO) is an example of an NO-releasing S-nitrosothiol (RSNO) molecule. GSNO exists in the human body as a result of NO (produced by epithelial cells, macrophages, sinus epithelial cells, etc.) reacting with oxygen to form NO. N2O3 is a nitrosonium ion (NO + ) to react with the thiol group of glutathione to form GSNO. As such, the nitric oxide generating formulations disclosed herein do not introduce any foreign or toxic substances into the nasal cavity / airway.

[0030] GSNO was prepared from glutathione (GSH) by acidifying a mixture of sodium nitrite / GSH with hydrochloric acid and then isolating the GSNO species (as solid crystals). Alternatively, GSNO can be a commercially available sample.

[0031] In some instances, moisture-activated S-nitrosothiol (RSNO) molecules other than GSNO can be used in nitric oxide-generating formulations. Examples of these other S-nitrosothiols include S-nitroso-cysteine ​​(CYSNO, naturally occurring in the human body), S-nitroso-N-acetyl-penicillamine (SNAP, which breaks down to the drug penicillamine), S-nitroso-penicillamine, and S-nitroso-albumin (naturally occurring in the human body).

[0032] In one example of a moisture-activated formulation, the RSNO powder is selected from the group consisting of S-nitrosoglutathione (GSNO), S-nitroso-cysteine, S-nitroso-N-acetyl-penicillamine, S-nitroso-penicillamine, and S-nitroso-albumin.

[0033] In a further example of a moisture-activated formulation, the stable NO donor / adduct is nitroprusside.

[0034] Some examples of S-nitrosothiols are also photoactivatable / sensitive. Examples of photoactivatable / sensitive S-nitrosothiols include S-nitroso-N-acetyl-penicillamine (SNAP) crystals, S-nitrosoglutathione (GSNO) crystals, and combinations thereof.

[0035] In the exemplary NO-generating formulations of the present disclosure, it is understood that one or more hydrophilic materials can be used as the hydrophilic binder. Some examples include polyvinyl acetate (PVA), poly(ethylene glycol) (PEG), polyacrylamide acetate, polyethylene oxide (PEO), polyethyl acrylate (PEA), polyvinylpyrrolidone (PVP), and modifications thereof (e.g., polyvinylpyrrolidone-vinyl acetate (PVP-VA)), for example, as physical blends or admixtures. Each polymer maintains its unique chemical properties. Various other hydrophilic polymers, such as hydroxypropyl cellulose (HPC), hydroxypropyl methylcellulose (HPMC), microcrystalline cellulose, corn starch, and / or combinations thereof, may also be used. It is also contemplated within the scope of the present disclosure that various polymers / copolymers, or combinations of polymers / copolymers, or other hydrophilic materials, can be used to provide hydrophilic binders with desired properties.

[0036] In one example, the weight average molecular weight of the hydrophilic polymer used may be from about 5000 Mw to about 500,000 Mw, or from about 10,000 Mw to about 200,000 Mw.

[0037] In one example, the hydrophilic binder is selected from the group consisting of polyvinyl acetate (PVA), poly(ethylene glycol) (PEG), polyacrylamide, acetate, polyethylene oxide (PEO), polyethyl acrylate (PEA), polyvinylpyrrolidone (PVP), polyvinylpyrrolidone-vinyl acetate (PVP-VA), hydroxypropyl cellulose (HPC), hydroxypropyl methylcellulose (HPMC), microcrystalline cellulose, corn starch, and combinations thereof.

[0038] The selected additive can control the release rate of nitric oxide from the NO donor / adduct after the formulation is exposed to an effective amount of water vapor, hydration fluid, or light. By including an additive in the formulation, the NO release profile can be controlled over time, thereby enhancing antibacterial activity and / or therapeutic benefit. In some cases, the additive accelerates the release rate of nitric oxide. In one example, the ratio (mol / mol) of NO donor / adduct to additive is 1:0.5 to 1:10.

[0039] Of course, the additive may be any suitable reducing agent. In one example of the NO-generating formulation, the additive is selected from the group consisting of reduced glutathione, cysteine, ascorbic acid or ascorbate, ascorbyl palmitate, copper ions, zinc ions, zinc oxide particles, organic selenium species, and combinations thereof. In one example, the organic selenium species is selected from the group consisting of selenocysteine ​​and ebselen. One example of a combination of additives is reduced glutathione and ascorbic acid.

[0040] Below are some examples of how additives can control or accelerate the rate of release of nitric oxide from RSNOs, specifically from GSNO. Glutathione can increase the rate of NO release from GSNO through the formation of an initial N-hydroxysulfanamide species (e.g., GS-N(OH)-SG). The initial N-hydroxysulfanamide species then converts to the radical GS. - Radical GS -can react with another GSNO molecule to release NO and form a GSSG disulfide species. Cysteine ​​can be transnitrosated with GSNO to form CysNO. CysNO releases NO significantly faster than GSNO. Ascorbic acid or ascorbate can be easily oxidized to form a smaller threose structure (a three-carbon sugar). Spontaneous oxidation of ascorbate can be coupled with the reduction of GSNO to release NO and GSH. Furthermore, the oxidation product of ascorbate, i.e., the smaller threose structure, is also a reducing agent. This reducing agent can donate electrons to GSNO, thereby contributing to the direct reduction of GSNO to NO. In one example, ascorbic acid or ascorbate can be oxidized in solution for up to 5 days, dried, and then incorporated into a nitric oxide-generating formulation. NO generation from GSNO can be catalyzed by organoselenium species. Any traces of free thiols present in GSH preparations can reduce copper or zinc ions to their +1 oxidation state, and Cu(I) or Zn(I) ions can then reduce GSNO to NO and GSH.

[0041] In one example, the NO-generating formulation further comprises a lubricant. When a lubricant is included, an example thereof is a surfactant selected from the group consisting of sodium stearate, zinc stearate, magnesium stearate, sodium laurate, zinc laurate, sodium palmitate, zinc palmitate, ascorbyl palmitate, and combinations thereof. Needless to say, a lubricant is not necessary for NO generation. However, in some examples, a lubricant can make the pellet more robust and modify (slow) the NO release kinetics. However, when the solid / pellet is compressed at a high enough pressure (e.g., greater than 40 kn), the pellet without lubricant should remain cohesive (although the resulting NO release may slow down in some cases as the compression pressure increases).

[0042] Of course, the components of the NO-generating formulation, including the NO donor / adduct, may be present in any desired amount. However, in one example, the stable NO donor / adduct (e.g., S-nitrosothiol (RSNO) powder) is present in an amount of about 1 wt% to about 50 wt%, or about 1 wt% to about 30 wt%, or about 3 wt% to about 12 wt% of the NO-generating formulation, and the hydrophilic binder is present in an amount of about 15 wt% to about 90 wt%, or greater than 0 wt% to about 82 wt%, or about 15 wt% to about 82 wt%, or about 25 wt% to about 82 wt% of the NO-generating formulation. the lubricant (if present in the formulation) is present in an amount of greater than about 0 wt% to about 15 wt%, or about 1 wt% to about 15 wt% of the NO-generating formulation, and the additive is present in an amount of about 0.5 wt% to about 65 wt%, or about 1 wt% to about 60 wt%, or about 3 wt% to about 60 wt% of the NO-generating formulation; and when zinc oxide particles are utilized as an additive, they may be present in an amount of about 1 wt% to about 90 wt% of the NO-generating formulation.

[0043] In another example, the NO-releasing formulation containing the NO donor / adduct is made alkaline (e.g., pH above 8.5) by adding an alkaline material. In this example, no additives / enhancers are included. At high pH (above about 8.5), GSNO is unstable, and NO is released without the addition of an additive / enhancer. Examples of alkaline materials are selected from the group consisting of sodium carbonate, a mixture of sodium carbonate and sodium bicarbonate, sodium hydroxide, potassium hydroxide, disodium hydrogen phosphate, trisodium phosphate, and combinations thereof.

[0044] In one example, the NO-generating formulation (including the NO donor / adduct) further comprises an inert material selected from the group consisting of sodium chloride, sodium bicarbonate, calcium chloride, microcrystalline cellulose, silicon dioxide, and combinations thereof. When an inert material is included in the formulation, it is present in an amount of greater than about 0 wt% to about 50 wt%, or about 5 wt% to about 25 wt% of the NO-generating formulation. As used herein, "inert material" refers to a material that does not significantly affect NO release (i.e., a material that changes the NO release rate by less than 10%). In the examples disclosed herein, the inert material can act, for example, as an anti-caking agent, a bulking agent, and / or a binder (although, of course, the inert material binder does not participate in water supply in the same way as a hydrophilic binder).

[0045] In one example, the NO-generating formulation (including the NO donor / adduct) further comprises a pH-regulating material. Of course, any suitable pH-regulating material can be used as desired. In one example, the pH-regulating material is selected from the group consisting of sodium phosphate buffer, potassium phosphate buffer, and combinations thereof. Other suitable pH-regulating materials include carbonates, other phosphates, or any other interfering materials that do not react with nitric oxide. The pH of the NO-generating formulation (including the NO donor / adduct) is greater than 9.5.

[0046] Some examples of NO-generating formulations (including NO donors / adducts) further include an absorbent to scavenge nitrogen dioxide (NO) released by the NO-generating formulation, a reagent to convert the generated NO back to NO, or a combination thereof. NO can be generated by reacting O with NO, which can be toxic to the recipient or patient. Therefore, it is desirable to remove any generated NO, convert any generated NO back to NO, or maintain extremely low levels of NO inhaled by the user. Absorbents may include soda lime scrubbers. If the NO content is greater than 1-3 ppm in the final gas phase, a soda lime scrubber can be used to remove excess NO. One example of a reagent or catalyst that can convert the generated NO back to NO is silica particles impregnated with ascorbic acid.

[0047] In another example, the NO-generating formulation containing the NO donor / adduct can be a two-component system, for example, when a deliquescent salt (e.g., calcium chloride) is used. The use of a highly hydrophilic material (e.g., a deliquescent salt such as calcium chloride) increases NO production because the pellets at least partially dissolve and thus behave like a solution.

[0048] The NO donor / adduct-containing moisture, hydrated liquid, or photoactivatable NO generating formulation may be in the form of a powder.

[0049] The moisture, hydrating liquid, or photoactivatable NO generating formulation containing the NO donor / adduct can also be applied as a coating or film to a surface using an adhesive that does not interfere with NO generation.

[0050] In yet another example, the moisture, hydrated liquid, or photoactivated NO generating formulation can be molded, shaped, pressed, or otherwise processed into a solid product of any suitable shape or size, such as a pellet, tablet, or disc. In some examples, the shaped solid product may be up to about 50 mm in diameter by about 25 mm thick. In one example, the shaped solid product may be about 5 mm in diameter by about 25 mm long. A size exceeding 50 mm by 25 mm may be undesirable in some cases, since the surface area to volume ratio is a criterion to consider along with water absorption tendency. The weight of the shaped solid product may be about 0.1 grams to about 5.0 grams, or about 0.2 grams to about 0.5 grams.

[0051] In one example, the NO-generating formulation 10, 10' comprises a single molded solid (i.e., the components of a moisture-activated formulation (e.g., RSNO, binder, and additives) are present in a single pellet, as opposed to a two-component system). One example of the NO-generating formulation 10 shown in FIG. 1A is in the form of two pre-formed single pellets, each of which includes a plastic sheath (a plastic sheath may be added, if desired, for mechanical rigidity to reduce pellet brittleness). Another example of the NO-generating formulation 10 shown in FIG. 1B is in the form of a pre-formed single pellet without a plastic sheath. In one example, the plastic sheath is polyethylene. One method for manufacturing the sheath is to insert the pre-formed pellet into polyethylene and then rupture the sheath with a needle to secure the pellet in place. The sheath may be of any suitable thickness, approximately 150 μm thick, as desired.

[0052] Of course, one or more single pellets can be used in conjunction with a container and / or inhalation device to provide the desired amount of gaseous NO.

[0053] An example of a liquid form of the NO-generating formulation is generated by reconstituting a solid or powder form of the NO-generating formulation containing the NO donor / adduct in a hydrating liquid, such as deionized water or purified water.

[0054] Instead of the NO donor / adducts described herein, another example of an NO-generating formulation includes a nitrite salt, which generates NO molecules when exposed to an acidic buffer and a pH between 4.1 and 7.5. The nitrite salt can be maintained in solid form (e.g., a powder) until it is desired to generate NO, or it can be maintained in aqueous solution (e.g., dissolved in water) until it is desired to generate NO.

[0055] The powder form of this exemplary NO generating formulation may contain nitrite alone or in combination with an additive and / or an oxygen scrubber.

[0056] The nitrite salt can be any water-soluble inorganic nitrite salt. Some water-soluble inorganic nitrite salts include alkali metal and alkaline earth metal nitrite salts. Specific examples include Li (lithium), Na (sodium), K (potassium), Rb (rubidium), Ca (calcium), and Mg (magnesium) nitrite salts. Most other metal salts are also soluble in water, such as Al (aluminum) and Fe (iron) salts. One specific example of a nitrite salt is NaNO2.

[0057] Nitrite may be present in the powder formulation in an amount up to 75 wt%. Upon reconstitution, the maximum nitrite concentration depends on the solubility of the salt. For example, the solubility limit of sodium nitrite is 12 mol / L at 25°C, and the solubility limit of potassium nitrite is 36.7 mol / L at 25°C. The lower end of the solubility range may be 10 μmol / L. In some instances, the reconstituted solution contains 8 mol / L NaNO2 and 13 mol / L KNO2.

[0058] Any additive that is a reducing agent may be included. In one example, the additive is ascorbate or ascorbic acid. In this formulation, the additive can reduce NO2 generation.

[0059] Oxygen scavengers may be used that can remove oxygen (which can react with NO to generate NO), thus reducing the amount of NO produced. Examples of suitable oxygen scrubbers are sodium metabisulfite, hydrazine, carbohydrazide, tannin, and diethylhydroxyamine (DEHA). The oxygen scrubber may be included in an amount of up to about 10 wt%.

[0060] In this example, the nitrite salt, used alone or in combination with an additive and / or oxygen scrubber, can be maintained in powder form until it is desired to reconstitute the powder with an acidic buffer to produce a liquid form of the NO generating formulation. The liquid form of the NO generating formulation has a pH greater than 4 to 7.5. The acidic buffer can be a mild acid capable of acidifying the nitrite salt to generate NO. In one example, the acidic buffer is monobasic and / or dibasic phosphate. Other examples of acidic buffers include monocitric acid, dibasic citric acid, acetic acid, bis-tris(2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol), MOPSO (β-hydroxy-4-morpholinepropanesulfonic acid), PIPES (1,4-piperazinediethanesulfonic acid), BES buffered saline, MOPS (3-(N-monofolino)propanesulfonic acid), TES (2-[[1,3-dihydroxypropyl]propanesulfonic acid]).

[0033] The preferred hydroxypropyl methylpropanesulfonate salts are N,N-bis[2-hydroxymethyl]propan-2-yl]aminoethanesulfonic acid, HEPES (4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid), DIPSO (3-(N,N-bis[2-hydroxyethyl]amino)-2-hydroxypropanesulfonic acid), TRIZMA® (2-amino-2-(hydroxymethyl)-1,3-propanediol), maleate, or cacodylate.

[0061] In another example, a kit is used to produce a liquid form of an NO-generating formulation (including nitrite). One example of a kit includes a first solution containing nitrite in water, and also includes a second solution containing an acidic buffer and an additive. Any example of a nitrite can be used in the first solution. Any example of an acidic buffer and any example of an additive can be used in the second solution.

[0062] In this example, the first and second solutions can be kept separate until it is desired to generate NO. When combined, the first and second solutions form a liquid form of the NO-generating formulation NO. The pH of this example liquid form of the NO-generating formulation NO also ranges from greater than 4 to 7.5.

[0063] Another example kit includes a powder formulation and a reconstitution solution. The powder formulation and reconstitution solution can be kept separate until it is desired to generate NO. When combined, the powder formulation and reconstitution solution are mixed to form a liquid form of the NO-generating formulation. In one example, the powder formulation includes an NO donor / adduct (and in some cases a hydrophilic binder), and the reconstitution solution includes a hydrating liquid and additives. In another example, the powder formulation includes a nitrite salt (and in some cases an oxygen scrubber), and the reconstitution solution includes an acidic buffer and a reducing agent additive.

[0064] In any of the NO-generating formulations, the solid (e.g., pellets / tablets / discs, etc.) or reconstituted liquid (e.g., pellets, tablets, or powder in hydration fluid, or liquid form containing nitrite and an acidic buffer) can be used in the system for a predetermined time (e.g., the user can be notified that "x" ppm of NO will be produced for "y" hours). The user can then be instructed to replace the pellets or introduce fresh liquid. In a further example, an NO detector can be used to indicate when the NO-generating formulation is no longer producing the desired amount of NO. In a further example, the solid can be formulated to dissolve when the NO-generating formulation is no longer producing the desired amount of NO.

[0065] container

[0066] Several different containers are contemplated herein. Some container examples function as outer packaging. The outer packaging protects the NO-generating formulation from premature water vapor and / or light exposure and / or premature hydration, and can be removed before use. Other container examples function to contain the NO-generating formulation during use (and thus may be NO-permeable). In some of the examples disclosed herein, the container with the NO-generating formulation is held inside the outer packaging container before use. Several different containers are described below.

[0067] Any of the exemplary NO-generating formulations disclosed herein may be contained within an outer package, such as a foil or a plastic pouch (e.g., biaxially oriented polyethylene terephthalate, such as commercially available MYLAR®). This type of outer package serves to hermetically seal the NO-generating material from moisture and light. This can affect the efficacy and time-release characteristics of the NO-releasing formulation, as well as its useful life. In some examples, the outer package hermetically seals a solid form of the NO-generating formulation. In these examples, the user would remove the solid NO-generating formulation, in the form of a pellet, disc, or tablet, from the outer package before use. In some examples, the outer package hermetically seals a pouch or other holder containing the NO-generating formulation. In these examples, the NO-permeable pouch or holder would be removed from the outer package before use. In some examples, the outer package hermetically seals a powder of the NO-generating formulation. In these examples, when the outer package is opened, the powder is optionally ready for hydration or acidic buffer exposure within the outer package itself. In yet another example, the outer package can be a single container with two chambers. One of these chambers is for the NO-generating formulation, and the second is for the hydration fluid or acidic buffer. The components of the two chambers can be mechanically forced to blend together. Such a container can also have a hole or membrane through which the NO can escape after mixing. In yet another example, the outer package hermetically seals an absorbent pad coated with or containing the NO-generating formulation. In these examples, the absorbent pad is removed from the hermetically sealed outer container for moisture and / or liquid activation. Yet another approach is to provide the NO-generating formulation in a premixed ampoule. The ampoule can be opened and poured into a device such as that shown in FIG. 26.

[0068] Other exemplary containers function to contain the NO-generating formulation during use (and may therefore be NO-permeable). An exemplary suitable container is a pouch.

[0069] The NO-permeable container can be a woven or nonwoven material (e.g., cloth, fabric, etc.). In some examples, the NO-permeable container is a rigid shell made of plastic, metal, or another material that does not interfere with NO generation and does not absorb / adsorb the generated NO. In one example, the NO-permeable container is selected from the group consisting of a woven material, a nonwoven material, a plastic material, and a metal material.

[0070] The NO-permeable container may be porous. The pores may be nanopores (e.g., about 1 nm to less than 1000 nm in diameter) or micropores (e.g., about 1 μm to less than 1000 μm in diameter).

[0071] If the NO-generating formulation is sensitive to water vapor, the container can be both humidified air-permeable and NO-permeable. This type of container allows humidified air to contact the nitric oxide-generating formulation and allows the generated gaseous NO to escape from the container. Examples of materials suitable for air- and NO-permeable containers include polyethylene, polyamide, polytetrafluoroethylene (PTFE), polypropylene, polyvinylidene difluoride, etc.

[0072] If the NO-generating formulation is photosensitive, the container may be transparent to blue and / or UV light and NO-permeable. NO-permeable and optically transparent materials for the container include polycarbonate, such as polycarbonate track-etched membranes. Commercially available NO-permeable and optically transparent materials include WHATMAN® NUCLEPORE® Track-Etched Membranes (GE Healthcare) and TRAKETCH® (Sabeu). These membranes may be nanoporous (e.g., about 1 nm to less than 1000 nm in diameter) or microporous (e.g., about 1 μm to less than 1000 μm in diameter).

[0073] Some example NO-permeable containers include attachment mechanisms that can be used to secure the NO-permeable container (and the NO-generating formulation therein) to the inside or outside of an inhalation device or another housing. Some example attachment mechanisms are shown in Figures 21-23.

[0074] In Figure 21, the container 32 is a pouch, and the attachment mechanism includes an adhesive 42 covered by a release adhesive liner 44. The adhesive 42 is positioned on one surface of the container 32, and the release adhesive liner 44 covers the adhesive 42 until it is removed by the user. One example of an adhesive is a pressure-sensitive adhesive or a double-sided adhesive. Once the release adhesive liner 44 is removed, the adhesive 42 can secure the container 32 to the inside of an inhalation device, such as a face mask 12, as shown in Figure 22.

[0075] Another example attachment mechanism is a clip. A clip 46 is shown schematically in Figure 23. One part of the clip 46 is attached to the container 32 (e.g., a pouch) and another part of the clip 46 is attached to the inhalation device, e.g., a face mask 12. Although a clip 46 is shown, it will be appreciated that other mechanical attachment mechanisms can be used in place of a clip. Examples include hooks, clamps, pins, or the like.

[0076] Any suitable method can be used to prepare the container 32, including molding, 3D printing, and the like.

[0077] Some example containers 32 further include a filter located on the surface of the container 32 or positioned outside the container 32. The filter includes an absorbent for scavenging nitrogen dioxide (NO) released by the NO-generating formulation, a reagent for converting the generated NO back to NO, or a combination thereof. In some examples, the filter is a nitrogen dioxide (NO) filter. The NO filter may be positioned to receive the output gas NO before it is inhaled by the patient. In some examples, the NO filter may be positioned outside the container 32 on a surface that will face the user's mouth and / or nose. Some example NO filters remove at least some of the nitrogen dioxide from the NO gas. For example, a silica gel filter (with pre-conditioned silica particles) or a soda-lime scrubber can be used as an NO filter. These filters can reduce NO to physiologically non-relevant levels. Other example NO filters convert nitrogen dioxide back to nitric oxide. This change is desirable because the NO payload is not lost in the form of scavenged (absorbed) NO2, but is reduced back to NO. An example of this type of NO2 filter is silica particles impregnated with ascorbic acid.

[0078] Inhalation devices

[0079] In some instances, the nitric oxide (NO) generating system further comprises an inhalation device in operable contact with the NO-generating formulation. Exemplary inhalation devices include face masks, nasal cannulae, nose pillows (also called "nasal vent plugs"), and ventilators.

[0080] In one example of an NO-generating system, the inhalation device includes a face mask 12. Figures 2-7 show various examples of suitable face mask configurations. Figures 22-24 also show various examples of suitable face mask configurations. The examples shown in Figures 22-24 also include various different containers 32. In some of the face mask 12 examples, the NO-generating formulation 10, 10' is manufactured separately and then introduced into the face mask 12. In other face mask examples, the NO-generating formulation 10, 10' can be manufactured as part of the face mask.

[0081] The face mask 12 (also known as a filtering respirator) can be used to protect the respiratory system from particles or chemicals. The face mask 12 can be configured to minimize the transmission of infectious diseases or protect the respiratory system from toxic substances or allergens in the ambient atmosphere. Additionally, the face mask 12 can be used to protect against the inhalation of industrial or urban dust or dirt, chemicals, allergens, etc., that may be present in the air. The face mask 12 can be used to maintain a closed space around the breathing orifice when a person is in close proximity to others or when undesirable airborne substances are present. Additionally, an infected person can wear the face mask 12 to protect others in close proximity to the pathogen. Of course, while the face masks disclosed herein are described in the context of humans, adaptations to any respiratory anatomical features are contemplated and disclosed herein. For example, the face mask can be adapted for dogs, cats, and horses.

[0082] In one example, the NO-generating formulation 10, 10' can be placed within the face mask (e.g., in the form of a solid disc, pellet, etc.) without being fixed or attached thereto. In this example, the NO-generating formulation 10, 10' is left loose within the face mask 12. In some embodiments, the NO-generating formulation 10, 10' is contained within an NO-permeable container 32, which can be placed within the face mask 12 without being fixed or attached thereto.

[0083] In another example, the face mask 12 includes a housing 14 (FIGS. 2A-2C and 3A-3C) for holding the NO-generating formulation 10, 10' in effective proximity to at least one of the user's mouth or nose. Figures 2C and 3C show the face mask 12 in position on the user's face, and also show the NO-generating formulation 10, 10' (FIGS. 2A-2C and 3A-3C) in effective proximity to at least one of the user's mouth or nose.

[0084] In the examples shown in Figures 2A-2C and 3A-3C, housing 14 selectively opens and closes. Figures 2A and 3A show the housing door in an open position (e.g., for use in introducing NO-generating formulation 10, 10' into face mask 12), and Figures 2B and 3B show the housing door in a closed position (e.g., for use when it is desired to introduce NO gas to a user).

[0085] The open configuration shown in FIGS. 2A and 3A depicts four single solid pellets / tablets disposed within the door of the housing 14. Each individual single solid pellet / tablet is an example of an NO-generating formulation 10, 10'. As such, the NO-generating formulation 10, 10' comprises a single solid object. Of course, any number of single pellets / tablets that produce a desired level of NO gas at a given time can be used as the NO-generating formulation 10, 10'. As such, when multiple single solid pellets / tablets are used together, the multiple single solid objects may be collectively referred to as the NO-generating formulation 10, 10'. In this instance, in some examples, the NO-generating formulation 10, 10' comprises multiple single solid objects.

[0086] 2A and 3A, each single pellet / tablet (e.g., NO-generating formulation 10, 10') may be snapped into place on the door of housing 14. In other examples, each single pellet / tablet (e.g., NO-generating formulation 10, 10') may be slid into a respective receptacle defined in the door of housing 14. Other suitable mechanisms may be used to retain a single solid form of NO-generating formulation 10, 10' within housing 14.

[0087] Although the door is shown as being capable of pivoting open and closed about an existing hinge, it will be appreciated that the housing door may be configured / designed to be selectively opened and closed by any suitable type of action, such as pivoting, sliding, flipping, etc. It will be appreciated that the housing 14 shown in Figures 2A-2C and 3A-3C is merely exemplary, and any suitable attachment structure or device may be used as the housing 14. For example, the housing of the face mask 12 may include a flap or pouch (internal or external) capable of receiving and holding the NO-generating formulation 10, 10'.

[0088] In the example of the face mask inhalation device (face mask 12) shown in FIG. 3A, the housing 14 further includes an air humidifier 22 in operative contact with the NO-generating formulation 10, 10′ (RSNO tablets / pellets), an air pump 20 in fluid communication with the air humidifier 22, and a power source (shown in the figure as a battery 24) operatively connected to the air humidifier 22 and the air pump 20. As shown in FIG. 3A, the housing 14 has an air inlet 18 defined therethrough. The air pump 20 may be connected to the air inlet so as to transport any water vapor generated by the air humidifier 22 through the air inlet 18 and thus to the vicinity of the NO-generating formulation 10, 10′. Of course, “fluid communication” should be interpreted broadly and includes, for example, liquids and gases.

[0089] As shown in FIG. 3B , the air humidifier 22 and air pump 20 are small enough to be mounted on or within the housing 14. The power of the battery 24 may be sufficient to operate both the air humidifier 22 and the air pump 20, or separate batteries 24 may be operably connected to the air humidifier 22 and the air pump 20. The air humidifier 22 can be used in any of the examples disclosed herein to generate moisture (e.g., water vapor) with or without moisture coming from the user's exhaled breath. The air pump 20 can be used to transport the generated water vapor near the NO-generating formulation 10, 10′ and can also transport the generated NO gas to the user.

[0090] A further example of a face mask inhalation device is not shown but is similar to the example system shown in FIG. 8. In this example, the face mask inhalation device includes an air pump 20 operably connected to the face mask 12, an air humidifier 22 in fluid communication with the air pump 20, and a container 32 for holding an NO-generating formulation 10, 10′, the container 32 being in fluid communication with the air humidifier 22 and the face mask 12. In yet another example, the inhalation device includes a gas mixer in fluid communication with the container, a second air pump operably connected to the gas mixer, an NO sensor operably connected between the gas mixer and the face mask, and a feedback controller operably connected to the NO sensor and the gas mixer. This example is similar to the system shown in FIG. 8 except that a nasal cannula 34 (FIG. 8) replaces the face mask 12. In this example, the face mask 12 may not have a housing 14 and may have an adapter for attaching a conduit (e.g., tubing) that is also in fluid communication with the container 32.

[0091] In still other examples, the housing 14 of the face mask 12 may be configured to receive and contain a liquid that produces NO gas. In some examples, the housing 14 at least partially defines a reservoir. The reservoir is adapted to receive a predetermined volume of hydration liquid in which the NO-generating formulation 10, 10′ is dissolved (or dispersed). In these examples, the solid NO-generating formulation 10, 10′ can be mixed with a specified / predetermined volume of water, and the reconstituted solution can then be poured into the housing 14. In another example, the housing 14 at least partially defines a reservoir. The reservoir is adapted to receive a predetermined volume of a liquid form of the NO-generating formulation in which nitrite is dissolved in an acidic buffer solution. In some of these examples, a powder containing nitrite can be mixed with a specified / predetermined volume of an acidic buffer solution, and the reconstituted solution can then be poured into the housing 14. In other of these examples, an aqueous solution of nitrite can be mixed with an acidic buffer solution, and the mixed solution can then be poured into the housing 14. In still other examples, the housing may contain an absorbent. The absorbent may be coated with the NO-generating formulation or may hold a liquid form of the NO-generating formulation.

[0092] One of these examples is shown in FIG. 26. In this example, the housing 14 partially defines a reservoir 60 and includes a reservoir wall 62 or filter 64 positioned between the interior of the face mask 12 and the interior of the reservoir 60. The reservoir wall 62 or filter 64 may be made of a nonporous, NO-permeable material, such as polyurethane, poly(tetrafluoroethylene), or the like. A reservoir wall 62 or filter 64 made of this type of material allows NO gas to pass therethrough (e.g., into the face mask 12) but also resists leakage of the hydrating liquid containing the solid NO-generating formulation 10, 10′, or the acidic buffer solution of other examples of liquid forms of NO-generating formulations. In other words, the reservoir wall 62 or filter 64 is impermeable to the hydrating liquid or acidic buffer solution and is NO-permeable. As such, the reservoir wall 62 or filter 64 allows NO gas generated within the reservoir 60 to be inhaled by the user without allowing the liquid to escape. When the filter 64 is positioned between the interior of the face mask 12 and the interior of the reservoir 60, the filter 64 may include an absorbent to scavenge nitrogen dioxide (NO2) released by the NO-generating formulation, a reagent to convert the generated NO2 back to NO, or a combination thereof.

[0093] In these examples, the housing 14 is not movable between open and closed positions (e.g., as shown in FIGS. 2A and 2B ) and may include a sealable input port 66 through which liquid may be introduced into the reservoir 60. A removable cap 68 may be used to seal the sealable input port 66.

[0094] 26, this example may further include an absorbent material within reservoir 60. The absorbent material absorbs liquid (e.g., an acidic buffer hydrating solution) but allows NO gas to exit the material and penetrate reservoir wall 62 or filter 64. Examples of absorbent materials that may be included within reservoir 60 include cotton balls or compressed cotton, or similar materials that do not affect the production of NO. In these examples, sealable input port 66 may be formed as a larger opening or door for introducing an absorbent pad and an example liquid form of the NO-generating formulation, or for introducing the NO-generating formulation and an activating liquid (e.g., water or an acidic buffer).

[0095] The reservoir 60 of FIG. 26 can also receive a container 32 containing a solid NO-generating formulation 10, 10'.

[0096] An alternative configuration not shown in FIG. 26 is to use a fan to blow the NO produced by the NO-generating formulation from the reservoir and towards the user of the inhalation device.

[0097] 26, it will be appreciated that this example device may include an additional filter containing a reagent or catalyst for converting any NO2 to NO. This filter may be positioned between the reservoir wall 62 or filter 64 and the interior of the face mask 12 to prevent NO2 from reaching the user.

[0098] The example shown in Figure 26 may include a diverter valve (not shown) that channels exhaled air from the device (e.g., face mask 12) without interacting with the reservoir 60 containing the NO-generating formulation. This valve configuration allows inhaled air to pass through the NO-generating system and into the user's mouth and nose.

[0099] The example shown in Figure 26 may include a chamber (fluidly connected to reservoir 60) in which released NO through a diverter valve during breath pauses and exhalation periods can be accumulated. The stored NO is then made available as a pulsed concentration during inspiration.

[0100] In any of the examples of face masks 12 that can receive a reconstituted solution or dispersion (e.g., a hydrating liquid containing NO-generating formulation 10, 10'), or in other examples of a liquid form of the NO-generating formulation, it will be appreciated that the housing 14 (and thus the reservoir 60) may be integrally formed with the face mask 12 or may be a separate housing 14 attached to the face mask 12.

[0101] The examples shown in Figures 4-7 illustrate several additional configurations for incorporating the NO-generating formulation 10, 10' into the face mask 12. Figures 4A and 4B illustrate another example of how multiple single pellets / tablets of the NO-generating formulation 10 may be placed within the housing 14. In this example, the housing 14 may include individual receptacles for the single pellets / tablets of the NO-generating formulation 10. Alternatively, the single pellets / tablets of the NO-generating formulation 10 may be secured to a cap ring that may be inserted into the housing 14.

[0102] The embodiments of Figures 5-7 also include check valves, such as an inhalation check valve 16 (Figures 2A-2C and 5), an exhalation check valve 16' (Figure 6), or both an inhalation check valve 16 and an exhalation check valve 16' (Figure 7). The check valves 16, 16' can help prevent exhaled air from returning into the NO-generating formulation 10, 10', because exhaled air could undesirably propel NO gas out of the system.

[0103] 5 and 7 also show a filter 26, which is positioned on the outside of the face mask 12 adjacent to the one-way check valve 16. This filter 26 may be an N95 or N99 filter.

[0104] In an example, the face mask 12 includes a filtering face mask. As used herein, a filtering face mask refers to a mask that covers at least the wearer's nose and mouth and includes a filter element 19 for removing contaminants and / or particles from the air passing through the filter element 19. As shown in FIG. 4A, the mask body 13 includes a filter element 19 molded to fit the contours of the wearer's face. As indicated by the airflow direction arrow 15, the filter element 19 is a two-way filter that filters inhaled and exhaled air. As shown in FIG. 4A, the housing 14 is mounted through and attached to the mask body 13. As shown in FIGS. 4A and 4B, the NO-generating formulation 10 is distributed around an aperture 17 defined in an inner wall 21 of the housing 14. In the example shown in FIG. 4A, the outer wall 23 of the housing 14 may be made of the non-porous, NO-permeable material described above. In another example, the outer wall 23 of the housing 14 may be made of a non-porous, NO-impermeable material. As shown in FIG. 5 , the inhalation check valve 16 opens to allow air to flow through the outer wall 23 of the housing 14 in the inhalation direction. The inhalation check valve 16 closes to block air from passing through the outer wall 23 of the housing 14 in the exhalation direction, which is opposite the inhalation direction. As shown in FIG. 5 , a filter 26 may be connected to the housing 14 to filter the air before it passes through the inhalation check valve 16. The filter 26 may have any desired filtering characteristics. For example, the filter 26 may be an N95 filter or an N99 filter. It is recognized that the filter 26 operates in parallel with the filter element 19. Therefore, the flow characteristics of the filter 26 and the filter element 19 are interdependent. For example, if it is significantly easier to draw air through the filter element 19 compared to the filter 26, most of the air will take the path of least resistance through the filter element 19.

[0105] The example shown in FIG. 6 is similar to the example shown in FIG. 4B in which an exhalation check valve 16′ is mounted on the mask body 13. When the exhalation check valve 16′ is open, it allows air to flow through the mask body 13 in an exhalation direction 26. When the exhalation check valve 16′ is closed, it blocks air from passing through the check valve 16′ in an inhalation direction opposite to the exhalation direction 27. In this way, the exhalation check valve 16′ allows at least a portion of the exhaled air to bypass the filter element 19, thereby reducing moisture that may accumulate in the interior space 20 defined by the face mask 12 and the wearer's face 31 (see, for example, FIG. 3C). As shown in FIG. 7, an example of the present disclosure may include a combination of the inhalation check valve 16 with the filter 26 shown in FIG. 5 and the exhalation check valve 16′ shown in FIG. 6.

[0106] 8, another example inhalation device includes an inhalation system including an air pump 20, an air humidifier 30 (hydrator) in fluid communication with the air pump 22, a container 32 (e.g., a canister) for holding an NO-generating formulation 10 (shown as several RSNO pellets / tablets inside a canister), the container 32 being in fluid communication with the air humidifier 22, and a nasal cannula 34 (or ventilator (not shown)) in fluid communication with the container 32. This example includes the configuration shown in the upper part of FIG. 8, but without the gas mixer 36 or NO sensor 38. However, it will be appreciated that the NO sensor 38 can be used in this configuration if desired.

[0107] In another example, the inhalation system further includes a gas mixer 36 in fluid communication with the container 32, a second air pump 20′ (shown at the bottom of FIG. 8) operably connected to the gas mixer 36, an NO sensor operably connected between the gas mixer 36 and the nasal cannula 34 (or ventilator), and a feedback controller 40 operably connected to the NO sensor 38 and the gas mixer 36.

[0108] The second air pump 20' introduces an oxygen-containing gas into the gas mixer, where it is mixed with NO gas to form an output gas that is delivered to an inhalation device (e.g., nasal cannula 34, or, alternatively, a face mask 12 or a ventilator). The oxygen-containing gas may be at least substantially pure oxygen gas, O2, or air, or a hypoxic gas containing oxygen. Although the air pump 20' is shown in FIG. 8, the oxygen-containing gas may be delivered from any suitable gas source, such as a compressed gas cylinder (not shown). The gas source may control the oxygen-containing gas flow rate or may be connected to a flow controller to control the amount of oxygen-containing gas flow into the gas mixer. Any suitable gas flow rate may be used. In one example, the flow rate of the oxygen-containing gas may be between about 50 mL / min and about 5 L / min. In another example, the flow rate of the oxygen-containing gas may be controlled so that the output gas stream contains between about 20% oxygen and about 99.99% oxygen. In one example, 100% air saturation may be used as the oxygen-containing gas. This corresponds to approximately 10 mg / L (ppm) O2 in the output gas stream.

[0109] Of course, an NO sensor 38 can be used to monitor the NO level in the output gas stream from the vessel 32 (or from the gas mixer 36, if present in the system). It is desirable to monitor the NO level to avoid the formation of NO (nitrogen dioxide, which can result from O reacting with NO and can be undesirable for the recipient / patient). Any suitable NO sensor 38 may be used.

[0110] In one example, the NO sensor 38 is a Shibuki-style sensor (not shown). This sensor converts NO to nitrate (NO3) at an inner platinum (Pt) electrode behind a gas-permeable membrane. - ) based on oxidation to

[0111] Another example of an NO sensor 38 is an amperometric NO sensor that exhibits a relatively rapid response time, and the large surface area of ​​the working electrode produces a larger current than the Shibuki configuration.

[0112] Some examples also include a NO2 sensor, which can be used to monitor the NO2 level in the output gas stream from vessel 32 (or from gas mixer 36, if present in the system).

[0113] For example, the NO sensor data (i.e., the NO concentration in the output gas stream and / or the NO2 concentration in the output gas stream) can be used by the feedback controller 40 to control the system to obtain at least a substantially constant NO concentration at the delivery end.

[0114] The target NO level may be based on the given application for which NO is being used. The target level may be very low or very high, depending on the patient and application. As an example, the target NO level for a neonate undergoing inhalation therapy may be about 10 ppm to about 70 ppm, and the target NO level to be generated to prevent platelet and other cell activation during bypass surgery may be about 190 ppm to about 210 ppm. Furthermore, in antibacterial applications, such as for pulmonary infections, lower NO levels may be useful during inhalation therapy, such as levels of about 500 ppb to about 10 ppm.

[0115] As discussed above, sensor data can also be used to determine whether undesirable amounts of NO are present in the output gas stream. If so, a system alarm can be activated. Additionally, a soda-lime scrubber or other NO scavenger can be included within the inhalation device just before the output gas stream is delivered to the patient via nasal cannula 34, face mask 12, nasal vent plugs (see FIGS. 25A-25C), or a ventilator (not shown). The soda-lime scrubber can remove excess NO if its content exceeds 1 ppm to 3 ppm in the final gas phase.

[0116] In other examples similar to FIG. 8 , a reservoir of hydrating liquid (e.g., water) can be provided instead of the air humidifier 22. The reservoir can be configured to introduce a predetermined / predetermined volume of hydrating liquid into the container 32 and thereby contact the NO-generating formulation 10, 10′ contained therein. Inside the container 32, the hydrating liquid activates NO gas generation. In some examples, the NO-generating formulation 10, 10′ is configured to release a predetermined volume of NO gas when mixed with a predetermined hydrating liquid. The NO gas can then be transported to the gas mixer 36, where it is mixed with an oxygen-containing gas and delivered to the patient. In these examples, the reservoir is refillable so that fresh hydrating liquid can be introduced. Additionally, the container 32 is refillable so that used liquid can be removed and fresh solid pellets / tablets of the NO-generating formulation 10, 10′ can be introduced after an NO gas-generating cycle has been performed.

[0117] In yet another example similar to FIG. 8, a reservoir of acidic buffer solution (with or without additives and / or oxygen scrubbers) can be provided instead of air humidifier 22. The reservoir can be configured to introduce a predetermined volume of acidic buffer solution into container 32, thereby contacting the nitrite salt (in powder or aqueous solution form) contained therein. Inside container 32, the acidic buffer solution acidifies the nitrite salt and activates NO gas generation. In some examples, the acidified nitrite salt is configured to release a predetermined volume of NO gas, e.g., about 1 ppm to about 250 ppm. The NO gas can then be transported to gas mixer 36, where it is mixed with oxygen-containing gas and delivered to the patient. In these examples, the reservoir is refillable, allowing fresh acidic buffer solution to be introduced. Additionally, container 32 is refillable, allowing spent solution to be removed and fresh nitrite salt (in powder or aqueous solution form) to be introduced after an NO gas generation cycle has been performed.

[0118] Although the face mask 12 and nasal cannula 34 are shown as examples of inhalation devices, it will be appreciated that a ventilator or any other device suitable for delivering an output gas flow to the airways of a user / patient may also be used in accordance with examples of the present disclosure.

[0119] In some examples, the NO-generating formulation 10, 10' is contained within an instance of a container 32, which is then introduced into the inhalation device. In some examples, the container 32 is simply placed inside the inhalation device. In other examples, such as those shown in Figures 21 and 22, the NO-permeable container 32 is affixed to the inhalation device via an attachment mechanism. In each of these examples, the inhalation device is a face mask 12.

[0120] 22, the inner surface of the face mask 12 (after the liner 44 has been removed) contacts the adhesive 42 and holds the reservoir 32 inside the face mask 12. The reservoir 32, and thus the NO-generating formulation (which in this example is moisture activated), is held in effective proximity to at least one of the user's mouth or nose.

[0121] 23, the inner surface of the face mask 12 includes a receiving portion that can secure the clip 46, and thus the container 32, to the face mask 12. Via the clip 46, the container 32, and thus the NO-generating formulation 10, 10' (which in this example is moisture-activated), is held in effective proximity to at least one of the user's mouth or nose.

[0122] 22 and 23, the user's breath delivers enough moisture to release the gaseous NO that is drawn into the nose and mouth during normal breathing. However, these examples may also include an air humidifier 22 and an air pump 20.

[0123] In other examples, the stable NO donor / adduct is activatable with blue light or ultraviolet (UV) light, and the NO generating system further includes a blue or UV light source 50 positioned to illuminate the NO generating formulation 10, 10'. In some examples, the NO generating formulation 10, 10' and the blue or UV light source 50 are positioned on or within the inhalation device in a manner that effectively illuminates the NO generating formulation 10, 10' to produce nitric oxide.

[0124] 24A shows an example of a photoactivated NO-generating system 47 inside an inhalation device (e.g., a face mask 12). In some examples, the photoactivated NO-generating system 47 includes an NO-generating formulation 10, 10' contained within a pouch (or other container 32). The pouch is NO-permeable and transparent to blue and / or UV light. In other examples, the NO-generating formulation 10, 10' may be chemically or physically attached to the inner wall of a housing 48 (without the container 32).

[0125] The example system 47 shown in FIG. 24A also includes a housing 48 in which the NO-permeable container 32 is mounted, a blue or UV light source 50 positioned within the housing 48 to illuminate the NO container 32, and a battery 24 operably connected to the blue or UV light source 50.

[0126] The housing 48 of the photoactivated NO generating system 47 can hold various components and allow the generated NO gas molecules to be released into the interior of the face mask 12 for inhalation by the user / patient. While the example shown in Figure 24A includes a housing 48 for an NO-permeable container (containing the NO-generating formulation 10, 10'), it will be appreciated that the NO-generating formulation 10, 10' may instead be coated as a film on the surface of the inhalation device. In these examples, a coating / film of the NO-generating formulation 10, 10' would be applied to the interior surface of the inhalation device, and a blue or UV light source 50 would be positioned inside the inhalation device to illuminate the coating / film.

[0127] Any blue or UV light source 50 can be used as long as it is capable of emitting light that initiates photolysis of the solid photosensitive NO donor / adduct. In other words, any light source 50 can be used as long as it is capable of emitting light of a specific wavelength that causes the NO donor / adduct to release nitric oxide. As such, the light source 50 can depend on the NO donor used and the desired rate of NO release. For example, the light source 50 can be a high-intensity light-emitting diode (LED), a laser diode, a lamp, or the like. In one example, the blue or UV light source 50 is a light-emitting diode. Suitable LEDs can have a nominal wavelength of, for example, about 340 nm to about 520 nm, e.g., 340 nm, 385 nm, 470 nm, or 500 nm. In one example, the blue or UV light source 50 emits light wavelengths of about 300 nm to about 520 nm at various intensities.

[0128] One or more light sources 50 can be used to release NO from the NO donor / adduct. Using multiple light sources 50 allows for further control of the amount of NO released. For example, if higher NO levels are desired, all of the light sources 50 (or coatings / films of the NO-donating formulation) facing the container 32 can be activated to emit light toward the NO donor / adduct, and if lower NO levels are desired, fewer than all of the light sources 50 can be activated. In some examples, the NO-generating formulation 10, 10' is configured to release a defined volume of NO gas when exposed to light wavelengths from about 300 nm to about 520 nm at various intensities.

[0129] In some examples, system 47 further includes control electronics 52 operably connected to blue or UV light source 50 and battery 24 operably connected to control electronics 52. Battery 24 may be a coin battery or other power source suitable for light source 50 and control electronics 52.

[0130] Some examples of the system 47 further include an NO sensor 38, a nitrogen dioxide (NO2) sensor, or a combination thereof.

[0131] 24A includes an NO sensor 38 positioned within a housing 48 and control electronics 52 positioned within the housing 48. Electronic circuitry (e.g., control electronics 52) can be operatively connected to the light source 50 to control when the light source 50 is turned on and off, the on-cycle time, intensity, power areal density, etc. In one example, the control electronics 52 controls the output of the light source 50 to produce a specified volume of NO gas.

[0132] The control electronics 52 may be part of a sensing and feedback system that includes an NO sensor 38 and a feedback controller 40 (not shown in FIG. 24A). The sensing and feedback system may also include an NO sensor (not shown in FIG. 24A). Feedback from the NO sensor 38 and the NO sensor may be used to servo-control one or more parameters of the light source 50 to achieve at least a substantially constant NO concentration at the delivery end.

[0133] Although the photoactivated NO generation system 47 in FIG. 24A is shown attached to the face mask 12, it should be understood that the photoactivated NO generation system in FIG. 24A may be incorporated into other inhalation devices. In some examples, the photoactivated NO generation system 47 shown in FIG. 24A is separate from and fluidly connected to the inhalation device. In these examples, the photoactivated NO generation system 47 shown in FIG. 24A includes a tube having a first end fluidly connected to the housing 48 and an adapter provided at a second end of the tube distal to the first end, such that the adapter is adapted to be attached to the face mask 12, nasal cannula 34, or respiratory tube (or ventilator). In this example, NO gas molecules are generated within the housing 48 upon exposure to blue and / or UV light, and then the NO gas molecules are transported through the tube to the inhalation device and then delivered to the user / patient. These examples may include a fan or suction device to transport NO from the housing 47 to the adapter. In one embodiment, the inhalation device shown in Figure 8 may be modified to include a photoactivated NO generation system 47. In this embodiment, the container 34 and air humidifier 22 shown in Figure 8 can be replaced with the photoactivated NO generation system 47 shown in Figure 24A.

[0134] Although the tubing and adapters are described in conjunction with the photoactivated NO generating system 47, it will be appreciated that these components can be similarly used with the moisture activated systems disclosed herein. Some of these examples will include an air humidifier 22, an air pump 20, and a power source to introduce an effective amount of water vapor into the housing. The housing contains the container 32 and the NO generating formulation 10, 10'.

[0135] If the NO donor / adduct is light- and moisture-activatable, it goes without saying that moisture and / or a hydrating liquid and / or UV or blue light 50 can be used to activate the NO donor / adduct in the NO-generating formulation 10. An example of this hybrid system 70 is shown in FIG. 24B. In this example, the photoactivated NO-generating system 47 (FIG. 24A) can include an additional chamber 72 surrounding the container 32 (containing the NO-generating formulation 10, 10′). This chamber 72 is liquid-impermeable, so that any introduced liquid or moisture does not interfere with the components of the photoactivated NO-generating system 47. This chamber 72 includes one wall (facing the light source 50) that is transparent to the emitted UV or blue light and another wall (facing the interior of the inhalation device) that is NO-permeable. The chamber 72 can receive a hydrating liquid. The hydrating liquid can activate the NO donor / adduct, or it can be operably connected to an air humidifier 22. An air humidifier can introduce enough moisture to activate the NO donor / adduct.

[0136] Further examples of NO-generating systems are shown in Figures 25A, 25B, and 25C. These example systems include nasal vent plugs or nose pillows. Each nasal vent plug includes a nitric oxide (NO)-impermeable housing 54 having integrally formed walls 55A, 55B, and 55C defining a partially enclosed interior portion 57, two nasal prongs 58 extending from one of the integrally formed walls 55A and in fluid communication with the partially enclosed interior portion 57, an air vent 56 defined in another of the integrally formed walls 55C for directing airflow into the partially enclosed interior portion 57, and a receptacle 59 within the partially enclosed interior portion 57, the receptacle 59 containing and adapted to receive an NO-generating formulation.

[0137] The nitric oxide (NO) impermeable housing 54 can be formed from any NO impermeable material. The material used to manufacture the housing 54 should not include silicone or other materials known to interact with (e.g., absorb) NO.

[0138] The integrally formed walls 55A, 55B, 55C of the housing 54 and the nose protrusion 58 may be one continuous piece of material formed by molding, 3D printing, or the like.

[0139] The nasal vent plug housing 54 includes an inlet vent 56. The vent 56 may be strategically positioned so that air is drawn through the NO-generating formulation into one of the nasal prongs 58. The vent 56 is preferably positioned at or near the side (wall 55C) of the housing 54, as opposed to the top of the housing 54. This placement can prevent NO from escaping through the vent 56. This placement can also help create a headspace within the enclosed interior portion 57. In the headspace, NO concentrations can build up during exhalation and during pauses in the user's natural breathing cycle. The stored NO is then available as a pulsed concentration during inspiration (discussed further below).

[0140] Each vent 56 may be in operative association with fins (not shown) positioned to help guide air through the vent 56 and into the enclosed interior portion 57.

[0141] The nasal prongs 58 may be shaped to be inserted into the user's nostrils, or to be positioned outside but near the user's nostrils. For example, the nasal prongs 58 may fit snugly just below the user's nostrils. In the latter example, the housing 54 may include a head strap 74 ( FIG. 25B ) to hold the nasal prongs 58 in a desired position on the user's face. As such, some examples of the NO generation system further include a head strap 74 secured to the housing 54. The housing 54 may include additional holes or another attachment mechanism (e.g., a hook and loop fastener) for securing the head strap 74. The head strap 74 may be adjustable. Of course, the nasal prongs 58 may be flush with the wall 55A (and thus not a true prong), and the head strap 74 may be used to hold the nasal vent plugs adjacent to the user's nostrils.

[0142] The nasal vent plug further includes a receptacle 59 within the closed interior portion 57. Various examples of the receptacle 59 are shown in Figures 25A-25C. The receptacle 59 holds an NO-generating formulation (e.g., in powder, liquid, or solid form) in effective proximity to the air vent 56 and nasal prongs 58.

[0143] 25A , the receptacle 59 is adapted to receive the container 32 having the solid form of the NO-generating formulation 10, 10′. In one example, the NO-generating formulation 10, 10′ comprises a single solid or multiple single solids within the container 32. The container 32 may be positioned between the inlet vent 56 and the inhalation opening 58. This positioning allows moisture and / or air from the vent 56, and in some cases from the user's exhaled breath, to enter the container 32 and activate the NO-generating formulation 10, 10′ contained within the container. This positioning also allows the generated NO gas molecules to be inhaled by the user through the nasal penetrations 58.

[0144] During use, the user inhales and exhales through the nasal penetrations 58. The moisture in the inhaled air may be sufficient to activate the NO-generating formulation 10, 10'. In another example, the nasal vent plug housing 54 may include an air humidifier 22 secured to the housing 54, and the air humidifier generates moisture. As shown in FIG. 25A, the system may include a fan (e.g., air pump 20) secured to the housing 54. The fan pushes the moisture (from the vents 56 or the air humidifier 20) toward the NO-generating formulation 10, 10'.

[0145] In the example shown in Figure 25A, the NO-generating formulation 10, 10' includes a stable NO donor / adduct that can be activated upon exposure to an effective amount of water vapor, the NO-generating formulation 10, 10' is contained within an NO-permeable container 32, and the receptacle 59 includes either a wall for attaching the NO-permeable container 32 or a slot for holding the NO-permeable container 32. The receptacle wall projects into the center of the housing 54 and can, for example, receive an adhesive 42 (similar to the example shown in Figure 22) or snap onto a clip 46 (similar to the example shown in Figure 23). The slot in the wall (shown in Figure 25A) can secure the container 32 in place.

[0146] In one example, the container 32 is permanently affixed by the receptacle 59, and in another example, the container 32 is removably affixed by the receptacle 59. If the container 32 (and thus the NO-generating formulation 10, 10′) is permanently secured within the housing 54 (e.g., via adhesive 42 or a slot), the entire nasal vent plug may be disposable (e.g., after its useful life). If the container 32 (and thus the NO-generating formulation 10, 10′) is removably secured within the housing 54 (e.g., via a slot), the nasal vent plug is reusable. In these examples, a new container 32 (and thus a new NO-generating formulation 10, 10′) can be introduced into the housing 54 and secured by the receptacle 59.

[0147] If the nasal vent plug is reusable, the housing 54 may further include a door 69 (above the nasal vent plug) defined within one of the integrally formed walls 55C. The door 69 is movable between a closed position and an open position that allows access to the receptacle 59. An example of a door 69 is shown in FIG. 25B.

[0148] Referring now specifically to FIG. 25B, some examples of receptacle 59 include a reservoir 60 for receiving a liquid form 73 of the NO-generating formulation.

[0149] In one of these examples, the system may include a solid form of NO-generating formulation 10, 10′, which can be reconstituted in a hydration liquid to generate liquid form 73 before the liquid form 73 is introduced into reservoir 60. In this example, the solid form of NO-generating formulation 10, 10′ includes a stable NO donor / adduct, a hydrophilic binder, and an additive for controlling the rate of NO release from the NO donor / adduct after the formulation is exposed to an effective amount of hydration liquid (e.g., water). Addition of the hydration liquid to the solid form can generate liquid form 73. The liquid form is then introduced into reservoir 60 through door 69.

[0150] In another of these examples, the system may include a solid form of the NO-generating formulation 10, 10′. This solid form can be reconstituted in an acidic buffer to produce liquid form 73 before the liquid form 73 is introduced into reservoir 60. In this example, the solid form of the NO-generating formulation includes a nitrite salt for producing NO upon exposure to an effective amount of an acidic buffer, and an additive for controlling the rate of NO release from the nitrite salt after the formulation is exposed to an effective amount of an acidic buffer. In this example, the solid form of the NO-generating formulation further includes an oxygen scrubber. Such a solid form of the NO-generating formulation is a powder that can be reconstituted with an acidic buffer. The acidic buffer can be added to the solid form to produce liquid form 73. The liquid form is then introduced into reservoir 60 through door 69.

[0151] In yet another of these examples, the system can include a kit for producing a liquid form of the NO-generating formulation 73. The kit includes a first solution including nitrite in water, and also includes a second solution including an acidic buffer and an additive for controlling the rate of NO release from the nitrite after the formulation is exposed to an effective amount of the acidic buffer. In this example, the first and second solutions can be mixed together and then added to the reservoir 60 / receptacle 59 through the door 69.

[0152] Another example of the receptacle 59 includes the reservoir 60, but further includes an absorbent pad 71 (e.g., cotton, compressed cotton, etc.). The absorbent pad is either contained within the reservoir 60 and adapted to be wetted with a liquid form of the NO-generating formulation, or is wetted with a liquid form of the NO-generating formulation and then introduced into the reservoir 60. In some examples, the absorbent pad 71 is incorporated into the reservoir 60, and some example of the liquid form 73 is then incorporated into the reservoir 60. In other examples, the absorbent pad 71 is wetted with some example of the liquid form 73 on the outside of the nasal vent plug and then incorporated into the reservoir 60. In still other examples, the absorbent pad 71 contains a solid form of the NO-generating formulation, which can be reconstituted in a hydration fluid or an acidic buffer. In this example, the solid form of the NO-generating formulation includes S-nitrosothiol (RSNO) powder, nitroprusside, or nitrite. For example, the absorbent pad 71 may include a coating of a powder form of the NO-generating formulation, and this coated absorbent pad 71 is incorporated into the reservoir 60. In some instances, a solid or powder is poured onto the absorbent pad 71 or placed into the reservoir 60 before (and therefore below) the absorbent pad 71.

[0153] A hydrating fluid or an acidic buffer (depending on the chemical properties of the NO-generating formulation within the coating) is then introduced into reservoir 60 to activate the NO donor / adduct or nitrite.

[0154] In any of these examples, the absorbent pad 71 can stabilize the liquid form 73 of the NO-generating formulation.

[0155] Receptacle 59, which is reservoir 60, may include walls that are impermeable to hydrating fluid or acidic buffer and permeable to NO.

[0156] The receptacle 59 / reservoir 60 can be sized to form a headspace within the closed interior portion 57, within which released NO can concentrate (e.g., during the user's breath pause and the time it takes to exhale) through an exhalation check valve (i.e., air diverter valve). The exhalation check valve redirects airflow around the closed interior portion 57, thereby allowing a higher concentration of NO to collect in the headspace. The stored NO then becomes available as a pulsed concentration during inspiration (as further described below).

[0157] Referring specifically to FIG. 25C , some examples of receptacle 59 can receive a cartridge, such as the photoactivated NO generating system 47 or 70 described in FIG. 24A or 24B. In this example, the NO generating formulation is activatable by blue or UV light, and the NO generating system further includes a cartridge (e.g., system 47 or 70) inserted or adapted to be inserted into receptacle 59, containing the NO generating formulation; a blue or UV light source 50 positioned to illuminate the NO generating formulation; and a battery 24 operably connected to the blue or UV light source 50. The cartridge operates similarly to system 47 shown and described in FIG. 24A and system 70 shown and described in FIG. 24B. Briefly, the activated blue or UV light source illuminates the NO generating formulation, thereby generating NO molecules. The NO molecules are delivered to the user through nasal prongs 58.

[0158] The example shown in Figure 25C can include an NO sensor 38 positioned within the cartridge and control electronics 52 positioned within the cartridge. This example can include an on-off switch 75 located on the exterior of the housing 54. The on-off switch turns the blue or UV light source 50 on or off. This example of a nose vent plug can be disposable or reusable.

[0159] Any example of a nasal vent plug (including those shown in FIGS. 25A, 26B, and 25C) can also include an air diverter valve (exhalation check valve 16′) for channeling exhaled air from the housing 54. This valve can direct exhaled air away from the NO-generating formulation, thereby maximizing the amount of NO delivered to the user. The air diverter valve can be controlled by control electronics 52 (e.g., an electronic controller). The electronic controller is connected to a sensor feedback loop and the NO sensor 38. Data from the sensor 38 can be used to divert air from the housing 54 or allow it to remain within the housing 54 so that the user receives an appropriate level of NO. The valve can also be controlled to a closed position, allowing NO to form in the headspace of the enclosed interior portion 57 during exhalation and during pauses in the user's natural breathing cycle. The control electronics 52 can also operate a fan or other mechanism to force a pulsed concentration during the user's inspiration.

[0160] Any of the examples of inhalation devices disclosed herein may include a nitrogen dioxide (NO) filter. The NO filter may be positioned, for example, in the tubing of a nasal cannula or ventilator, or within a face mask, or within the nasal prongs 58 of a nasal vent plug to receive the output gas before it is inhaled by the patient. Any of the NO filter examples described herein may be used. As an example, any of the nasal vent plugs shown in FIGS. 25A-25C may include a filter positioned between the receptacle 59 and the nasal prongs 58. The filter may include an absorbent to scavenge nitrogen dioxide (NO) released by the NO-generating formulation, a reagent to convert the generated NO back to NO, or a combination thereof.

[0161] Furthermore, in any of the examples disclosed herein utilizing any of the liquid forms of the NO-generating formulation, an additional NO-permeable membrane can be positioned over reservoir 60. In some instances, aerosol droplets may be generated along with the NO gas. Aerosol droplets are undesirable for various medical applications. Needless to say, the NO-permeable membrane prevents aerosol droplets from being generated and / or leaving reservoir 60 along with the NO gas. Examples of types of NO-permeable membranes that prevent the formation of aerosol droplets include porous polytetrafluoroethylene (PTFE), polypropylene, polyethylene, polyamide, polyvinylidene difluoride, and the like. Examples of types of NO-permeable membranes that prevent the escape of aerosol droplets include polycarbonate, e.g., polycarbonate track-etched membranes.

[0162] Another mechanism for preventing aerosol droplets from being transported with the NO gas stream involves positioning a highly porous droplet catcher (eg, gauze).

[0163] In any of these examples, this type of NO-permeable membrane can be positioned at the opening of the reservoir 60, or specifically within the nasal vent plug, between the opening of the reservoir 60 and the nasal prongs 58, or within the nasal prongs 58.

[0164] The examples disclosed herein can produce effective amounts of NO for delivery to a user / patient via inhalation. The elevated levels of NO produced are therapeutic and sufficient to kill bacteria and viruses, disrupt bacterial biofilm formation, dissipate or prevent microbial biofilm formation (e.g., dissipate antibiotic-resistant biofilms), reduce platelet aggregation and thrombus formation, reduce inflammation, and increase ciliary beating frequency, thereby improving mucociliary clearance. Increased NO production by the examples of the present disclosure can be observed almost immediately and over extended periods of time (e.g., about 4-96 hours).

[0165] In some of the examples disclosed herein, the level of gas-phase NO within the nasal cavity / airway as a result of inhaling gaseous nitric oxide produced from the moisture-activated NO-generating formulation may be between 50 parts per billion by volume (ppbv) and approximately 7500 ppbv. In other examples disclosed herein, the NO-generating formulation contained within the pouch or other container 32 releases a desired volume of NO, e.g., 10 ppm, 20 ppm, or 30 ppm on average, with a desired design range of 1 ppm to 250 ppm over a time range of 0.5 to 3 hours or more. In the example of a nose pillow (nasal vent plug), the NO-generating capacity of any example of the reconstituted NO-generating formulation (e.g., liquid form 73) may be formed in a range of 5 ppm to 50 ppm, with a desired design range of 1 ppm to 250 ppm.

[0166] To further illustrate the present disclosure, examples are presented herein. It should be understood that these examples are provided for illustrative purposes and should not be construed as limiting the scope of the disclosure.

[0167] Of course, the NO release data below and for Figure 9 (see below) was generated from pellets without a plastic sheath. [Example]

[0168] Example 1

[0169] formulation

[0170] All moisture-activated NO generating formulations were prepared similarly. The ingredients were thoroughly mixed together until the mixture appeared homogeneous. The mixture was then placed in a circular manual pill press, e.g., a 5 mm diameter manual pill press. The mixture was compressed to form a solid pellet. The pellet was then removed by removing the bottom stop and pressing the pellet further. This produced pellets approximately 10 mm long and 5 mm in diameter. The size of the pellets varied depending on the target gas generating capacity of the design.

[0171] NO release rate

[0172] The NO release rates of the formulations were measured at room temperature by an electrochemical nitric oxide analyzer (NOA) in an amber NOA cell while purging with 50 mL / min of humidified nitrogen (approximately 80% relative humidity (RH)) through a glass pipette.

[0173] Stability measurements

[0174] The stability of the formulations was tested via UV / Vis analysis and / or via electrochemical NOA.

[0175] GSNO Results

[0176] Figures 9-20 show the NO release kinetics of the various test formulations.

[0177] Formulation A (Figure 9) used GSNO, ascorbic acid (3.5 wt%) as an enhancer, and cornstarch (71 wt%) as a hydrophilic binder, along with an inert salt (a mixture of sodium chloride and sodium bicarbonate) (21.5 wt%). Pellets of this mixture disintegrated easily.

[0178] Formulation B, Figure 10, used GSNO (6.4 wt%), ascorbic acid (13.8 wt%) as an enhancer, and a commercial excipient blend (FIRMAPRESS® excipient) for the hydrophilic binder (79.8 wt%). This excipient blend is representative of a common blend used to prepare pills for ingestion, which improved pill integrity.

[0179] Formulation C, Figure 11, used GSNO (10.6 wt%), ascorbic acid (22.9 wt%) as an enhancer, and hypromellose (71 wt%) as a hydrophilic binder. Hypromellose is another common ingredient in manufacturing ingestible pills for commercial excipient formulations. This formulation was not as mechanically robust as the previous formulation B.

[0180] Formulation D, Figure 12, used GSNO (8.1 wt%), ascorbyl palmitate (41.1 wt%) as an enhancer (palmitate acts as a lubricant), and hypromellose (50.8 wt%) as a hydrophilic binder. Compared to Formulation C, it improved pill compression properties because it lubricated the press. This also indicates that the addition of a lubricant reduces the NO release rate.

[0181] Figure 13 shows another batch of Formulation D, demonstrating that the NO release kinetics were similar between batches.

[0182] Formulation E, FIG. 14, which contained only 1% GSNO in the formulation, along with ascorbic acid (about 10 wt%) as an enhancer and about 90% hydrophilic binder, produced about 50 ppbv of NO.

[0183] Formulation F used GSNO (40 wt%), cysteine ​​(25 wt%) as an enhancer, and hypromellose (35 wt%) as a hydrophilic binder. NO release from Formulation F (high percentage of GSNO and cysteine) is shown in Figure 15A.

[0184] Formulation F, Figure 15B, shows the dependence of NO production on percent relative humidity (%RH). At zero humidity, the NO production rate is relatively low, less than 200 ppbv, which is likely due to the small amount of residual moisture in the system. At moderate humidity, approximately 44% RH, the rate is significantly higher, and at very high humidity, approximately 80% RH, the rate is three times that of 44% RH.

[0185] Formulation G, Figure 16, shows that a very high percentage of enhancer, 60% ascorbyl palmitate, can produce effective NO levels. Formulation G also contained 12 wt% GSNO and 25 wt% FIRMAPRESS® excipient as a hydrophilic binder.

[0186] Formulation H, Figure 17, shows that a very low percentage of enhancer, 0.8% copper sulfate, can produce effective NO levels. Formulation H also contained 8 wt% GSNO and 91 wt% hypromellose as a hydrophilic binder.

[0187] Formulation I, Figure 18, shows that the hydrophilic compound, calcium chloride (a deliquescent salt) (62 wt%), combined with glutathione (30 wt%) as a promoter, is highly effective in generating NO. Formulation I also contained 8 wt% GSNO.

[0188] Formulation J, Figure 19, shows NO production with a high level of salt, disodium hydrogen phosphate (46 wt%). Formulation J also contained 7 wt% GSNO, 15 wt% ascorbic acid as an enhancer, and 32 wt% hypromellose (24 wt%) as a hydrophilic binder mixed with FIRMAPRESS® excipient (8 wt%).

[0189] Formulation K contained 8 wt% GSNO, 50 wt% disodium hydrogen phosphate, and 42 wt% FIRMAPRESS® excipient. Formulation K, Figure 20, shows that disodium hydrogen phosphate (50 wt%), a base that provides an alkaline pH when dissolved, is effective as an enhancer (RSNOs are relatively unstable in alkaline conditions). GSNO instability, and therefore NO production, begins to increase above pH 8.5. Instability increases as the pH increases above 8.5.

[0190] Example 2

[0191] Nasal vent plugs (or nasal pillows) similar to those shown in Figure 25B were prepared.

[0192] An NO donor formulation containing sodium nitrate, sodium ascorbate, sodium dihydrogen phosphate, and disodium hydrogen phosphate was prepared. 1.5 mL of deionized (DI) water was also added. Table 1 shows the components of the NO donor formulation. [Table 1]

[0193] The NO-generating formulation was introduced into the reservoir of the nasal vent plug. A steady airflow was directed through the vent at a flow rate of 7.5 L / min. NO and NO2 levels were measured at the nasal prongs. The results are shown in Figure 27. These results demonstrate that NO is produced at the desired levels. NO2 levels can be further reduced by incorporating an oxygen scrubber and / or filter.

[0194] References throughout this specification to "one example," "another example," "an example," etc. mean that a particular element (e.g., a feature, structure, and / or characteristic) described in connection with that example is included in at least one example described herein and may or may not be present in other examples. In addition, unless the context clearly dictates otherwise, elements described with respect to any example can be combined in any suitable manner in various examples.

[0195] Of course, ranges provided herein include the stated range and any value or subrange within the stated range. For example, a range of about 3 wt% to about 12 wt% should be interpreted to include not only the explicit limits of about 3 wt% to about 12 wt%, but also individual values, such as 5 wt%, 6.2 wt%, 9.85 wt%, etc., and subranges, such as about 4 wt% to about 10 wt%, etc. Furthermore, when "about" is used to describe a value, it is intended to include slight variations (up to + / - 10%) from the stated value.

[0196] In describing and claiming the examples disclosed herein, the singular forms "a," "an," and "the" include the plural forms unless the context clearly dictates otherwise.

[0197] Although several examples have been detailed, it should be understood that the disclosed examples may be modified, and therefore the above description should be considered non-limiting.

Claims

1. 1. A nitric oxide (NO) generating system comprising: It is an NO-generating preparation, stable NO donors / adducts, a hydrophilic binder selected from the group consisting of polyvinyl acetate (PVA), poly(ethylene glycol) (PEG), polyacrylamide, acetate, polyethylene oxide (PEO), polyethyl acrylate (PEA), polyvinylpyrrolidone, polyvinylpyrrolidone-vinyl acetate (PVP-VA), hydroxypropyl cellulose (HPC), hydroxypropyl methylcellulose (HPMC), microcrystalline cellulose, corn starch, and combinations thereof; and an additive selected from the group consisting of reduced glutathione, cysteine, ascorbic acid or ascorbate, ascorbyl palmitate, copper ions, zinc ions, zinc oxide particles, organic selenium species, and combinations thereof; an NO-generating formulation, wherein the additive is for controlling the rate of release of NO from the stable NO donor / adduct after the formulation is exposed to an effective amount of water or water vapor; air pump, an air humidifier in fluid communication with the air pump; a container holding an NO-generating formulation, in fluid communication with the air humidifier; and an inhalation device including a nasal cannula or ventilator in fluid communication with the container; A nitric oxide (NO) generating system comprising:

2. 2. The NO generating system of claim 1, wherein the NO generating formulation further comprises a lubricant selected from the group consisting of sodium stearate, zinc stearate, magnesium stearate, sodium laurate, zinc laurate, sodium palmitate, zinc palmitate, ascorbyl palmitate, and combinations thereof.

3. the stable NO donor / adduct is an S-nitrosothiol (RSNO) powder present in an amount of 3 wt % to 12 wt % of the NO-generating formulation; the hydrophilic binder is present in an amount of 15 wt % to 82 wt % of the NO-generating formulation; the lubricant is present in an amount of 1 wt % to 15 wt % of the NO-generating formulation; and the additive is present in an amount of 3 wt % to 60 wt % of the NO-generating formulation; The NO generating system of claim 2.

4. 2. The NO generating system of claim 1, wherein the NO generating formulation further comprises an inert material selected from the group consisting of sodium chloride, sodium bicarbonate, calcium chloride, microcrystalline cellulose, silicon dioxide, and combinations thereof.

5. 5. The NO generating system of claim 4, wherein the inert material is present in an amount of greater than 0 wt% to 50 wt% of the NO generating formulation.

6. 2. The NO generating system of claim 1, wherein the ratio (mol / mol) of the stable NO donor / adduct to the additive is 1:0.5 to 1:

10.

7. 2. The NO generating system of claim 1, wherein the NO generating formulation is in the form of a single solid selected from the group consisting of a pellet, a tablet, or a disc.

8. 8. The NO generating system of claim 7, wherein the NO generating formulation is in the form of a plurality of single solids selected from the group consisting of pellets, tablets, or discs.

9. The inhalation device further comprises: a gas mixer in fluid communication with the vessel; a second air pump operably connected to the gas mixer; an NO sensor operatively connected between the gas mixer and the nasal cannula or ventilator; a feedback controller operatively connected to the NOx sensor and the gas mixer; 2. The NO generating system of claim 1, comprising:

10. 10. The NO generating system of claim 9, wherein the second air pump introduces oxygen-containing gas into a gas mixer, and the gas mixer mixes the oxygen-containing gas with the NO gas from the container and delivers it to the nasal cannula or the ventilator.

11. 2. The NO generating system of claim 1, wherein the organic selenium species is selected from the group consisting of selenocysteine ​​and ebselen.

12. 2. The NO generating system of claim 1, wherein the stable NO donor / adduct is an RSNO powder selected from the group consisting of S-nitrosoglutathione (GSNO), S-nitroso-cysteine, S-nitroso-N-acetylpenicillamine, S-nitroso-penicillamine, and S-nitroso-albumin.

13. 2. The NO generating system of claim 1, wherein the stable NO donor / adduct is nitroprusside.

14. 10. The NO generating system of claim 1, wherein the NO generating formulation further comprises a pH controlling material selected from the group consisting of sodium phosphate buffer, potassium phosphate buffer, and combinations thereof.

Images